PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2014New England Journal of Medicine2,825 citationsOpen Access

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

View Full Paper
MGMark R. GilbertJDJames J. DignamTATerri S. Armstrong

Key Points

  • This trial aims to assess the impact of bevacizumab on overall and progression-free survival in newly diagnosed glioblastoma.
  • Randomized trial assessing first-line treatment with bevacizumab in patients with newly diagnosed glioblastoma.
  • ClinicalTrials.gov number: NCT00884741.
  • Bevacizumab did not improve overall survival in glioblastoma patients.
  • Progression-free survival was prolonged but did not meet the prespecified improvement target.

Abstract

First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma. Progression-free survival was prolonged but did not reach the prespecified improvement target. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00884741.).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Gilbert et al. (2014) studied this question.

synapsesocial.com/papers/69d90478f544bba627bedf1dhttps://doi.org/10.1056/nejmoa1308573
Ask AI
Helpful
Bookmark
Share
View Full Paper